May 31, 2017

Janssen @ASCO 2017

Janssen will present new data for both approved and investigational oncology compounds at ASCO 2017 Annual Meeting. 19 company-sponsored abstracts have been accepted for presentation, including for abiraterone acetate, daratumumab and ibrutinib. Most notably, Phase 3 pivotal trial results for abiraterone acetate will be featured in the ASCO Press Briefing […]